CPRI’s small-scale services will add to Lonza’s cGMP capabilities.


Lonza and California Peptide Research (CPRI) are joining forces to more effectively serve customers requesting peptide manufacturing and development services. CPRI’s high-quality small-scale services will complement Lonza’s capabilities in custom cGMP peptide manufacturing and development.

The alliance aims at providing customers with a more complete offering that spans research through to commercial supply. It will also enable a seamless transition of custom peptide projects between CPRI’s small-scale facility and Lonza’s cGMP facilities.

Based in San Franciscon, CPRI’s customer base in North America will add to Lonza’s existing facilities in Braine-l’Alleud (Belgium), Visp (Switzerland), Nansha (China), and Kourim (Czech Republic).








This site uses Akismet to reduce spam. Learn how your comment data is processed.